Malaysia vs Morocco: Average cost of multi drug-resistant tuberculosis treatment
Malaysia
2,000 constant 2022 US$
in 2024
Morocco
2,000 constant 2022 US$
in 2024
Malaysia rank
22nd
Morocco rank
22nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Malaysia
- Morocco
How they compare
Malaysia currently reports 2,000 constant 2022 US$ against 2,000 constant 2022 US$ in Morocco, a difference of 0 constant 2022 US$.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Malaysia ahead.
Malaysia ranks 22nd and Morocco ranks 22nd of 92 countries.
Across the 2 decades both report, Malaysia averaged higher in 1 and Morocco in 1.
Head to head by decade
| Decade | Malaysia | Morocco | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,000 constant 2022 US$ | 2,127 constant 2022 US$ | 126.67 constant 2022 US$ | Morocco |
| 2020s | 2,000 constant 2022 US$ | 1,644 constant 2022 US$ | 355.8 constant 2022 US$ | Malaysia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Malaysia or Morocco?
- Malaysia, at 2,000 constant 2022 US$ against 2,000 constant 2022 US$ in Morocco as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Malaysia and Morocco?
- 0 constant 2022 US$, with Malaysia ahead.
- How many years of comparable data are there for Malaysia and Morocco?
- 8 years are reported by both, from 2017 to 2024.
- How do Malaysia and Morocco rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Malaysia ranks 22nd and Morocco ranks 22nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.